The resumption of production at Pfizer's Rocky Mount facility and the launch of a new line in the sterile injectable manufacturing area could potentially increase Pfizer's production capacity, which could have a positive impact on its stock. However, the delay in full supply of some medicines until next year could negatively impact its short-term revenues, which could put downward pressure on the stock. Therefore, the net impact on the stock is neutral.